Similar to other immunotherapies, TIM-3 blockade may bring autoimmune or inflammatory side effects, such as over-immune activation and myelosuppression, etc. Moreover, new immune escape pathways may emerge in the tumor cells and the microenvironment, which may lead to secondary drug resistance. This evidence concerns the gene HAVCR2 and neoplasm.